Month: January 2022

Release – BioSig to Present at the 27th Annual International AF Symposium

Posted on by Admin



BioSig to Present at the 27th Annual International AF Symposium

News and Market Data on BioSig Technologies

 

PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health

Westport, CT, Jan. 07, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting at the 27th Annual International Atrial Fibrillation Symposium on January 13-15, 2022.

Clinical observations collected with BioSig’s PURE EP™ System will be presented by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health during Spotlight Session: Complex AF Case Study Utilizing a New Standard in Signal Processing on January 13, 2022, from 8:30-9:30 AM ET.

“Dr. Lakkireddy is highly regarded for his passionate commitment to those suffering from complex arrhythmias and for his leadership in the field of electrophysiology, and we are thrilled to have him represent our technology at this benchmark industry event. We would like to thank the course directors, Drs. Ruskin, Mansour, Reddy, Keane, Jais, and the entire faculty for bringing the electrophysiology community together during this important industry event. We look forward to reconnecting with our physician partners and our peers as we gear up for an impactful clinical and commercial year,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

During the event, BioSig will be exhibiting at booth 403. The Company’s executive, commercial and clinical teams will host demonstrations of the PURE EP™ System and some of its platform technology’s latest software and algorithmic features for arrhythmia care.

The conference will also be broadcast live. To register for the event and stream the live presentation, please follow this link: https://register.rcsreg.com/r2/afs2022/ga/top.html

To date, more than 73 physicians have completed over 1800 patient cases with the PURE EP™ System. The Company is in a focused commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida.

Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources.

One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.

About 277h Annual International AF Symposium
This intensive, highly focused three-day symposium brings together the world’s leading medical scientists to share in a highly interactive environment the most recent advances in the field of atrial fibrillation. The primary objective of the meeting is to provide attendees with a thorough and practical course on the current state of the art in the field of atrial fibrillation in a scholarly and collegial atmosphere, as well as an opportunity to network with colleagues and faculty between sessions. More information about the event on  www.afsymposium.com.

About BioSig Technologies


BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

1 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4

Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880,
aballou@biosigtech.com
203-409-5444, x133

Source: BioSig Technologies, Inc.

Update on DWAC the Trump Media SPAC

Posted on by Admin 


	Image Credit: Gage Skidmore (Flickr)

The Latest on Digital World Acquisition Corp’s Progress (Trump Media SPAC Deal)

 

On October 20, 2021, the Trump Media and Technology Group entered into a definitive merger with Digital World Acquisition Corp. (DWAC). The company’s main product, still in development, is a Twitter-like platform with a promise to encourage, “an open, free, and honest global conversation without discriminating against political ideology.”

At the time the former President said, “I created TRUTH Social and video-on-demand service (TMTG+) to stand up to the tyranny of Big Tech.”

DWAC is now up over 500% from its $10 IPO price, but well off its 845% moonshot after the merger announcement in October. DWAC also filed for a $1B PIPE deal for the social media company in December.

 

 

SPAC, Digital World Acquisition Corp. skyrocketed an additional 20% yesterday (January 6). The move followed a report that the TRUTH Social app is set to be launched in February.

Truth Social’s listing on Apple’s app store has an expected start date of Feb. 21.

In December, Trump Media & Technology announced that Representative Devin Nunes (R-CA) will take the role of chief executive officer of Trump’s social media platform. The former dairy farmer has since resigned from Congress to fulfill this new role.

 

Suggested Reading:



Optionality of a Special Purpose Acquisition Company

Regulation of a Special Purpose Acquisition Company





Analysis of a Special Purpose Acquisition Company

Lifecycle of a Special Purpose Acquisition Company

 

Sources:

https://truthsocial.com/

https://clerk.house.gov/members/CA22/vacancy

https://www.globenewswire.com/news-release/2021/12/04/2346139/0/en/Trump-Media-Technology-Group-Corp-and-Digital-World-Acquisition-Corp-Announce-1-Billion-PIPE-Investment-in-Committed-Capital-to-Fund-Business.html

https://www.dwacspac.com/

www.koyfin.com

https://seekingalpha.com/pr/18589421-congressman-devin-g-nunes-ranking-member-of-house-intelligence-committee-to-join-trump-media

 

Stay up to date. Follow us:

 

FenixOro Provides Letter to Investors Outlining Plans for 2022

Posted on by Admin



FenixOro Provides Letter to Investors Outlining Plans for 2022

Research, News, and Market Data on FenixOro Gold

 

TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) — FenixOro Gold Corp. (CSE: FENX; OTCQB: FDVXF; Frankfurt: 8FD) is pleased to provide an update to shareholders and investors as the Company kicks off its plans for 2022.

As we set out on a new year we wanted to share with you our objectives for what we believe will be an exciting time as we accelerate the exploration program at the Abriaqui gold project.

Our plans for 2022 are being driven by the tremendous success we had last year. The achievements were many. To provide some context for the upcoming program, here are some of the key developments we announced last year (www.fenixoro.com/news-events/press-releases/)

2021 Highlights

  • The significant discovery of a new zone with multiple high grade intercepts including 124 g/t gold (February 24/21)
  • Extending strike length of 1400m on the main Santa Teresa vein (March 15/21)
  • Completion of Phase 1 drilling and the establishment of a preliminary minimum target resource model of 1.6 – 2.4 million oz (March 19/21)
  • Demonstrating the significant vertical continuity of high grade mineralization, a minimum of 1200 meters (March 19/21)
  • The commencement of Phase 2 drilling (April 26/21)
  • Significant soil anomalies generated large target areas in the undrilled Southern block (May 10/21)
  • True-width channel sample intercept of 11.4m of 6.08 g/t gold on the main Santa Teresa vein system (August 5/21)
  • Noble Capital Markets initiated research coverage (September 13/21)
  • Intercepted 23.2 g/t gold in the newly discovered Cascada vein (September 28/21)
  • Closing on a first tranche private placement financing of $2.4 million (December 8/21)
  • Cormark Securities issued a report following a site visit by Mining Analyst Brock Colterjohn (December 9/21)

One of the main challenges we faced in 2021 was the turnaround time it took to receive assay results from the lab – at times this ran ten to twelve weeks due to global supply issues. We have addressed this and are now using a new lab that is providing results on a fourteen day turnaround. This should provide us with a much more consistent data and news flow. We are currently in the midst of a major data compilation exercise that we expect will generate new interpretations as well as high-interest target areas.

Looking Forward
With the foundation of the success we experienced in 2021 we are extremely optimistic on the outlook for 2022. It is still very early in the exploration cycle of the project and yet we are already demonstrating that Abriaqui has the potential to be a significant and very special asset.

The three key objectives of this year’s program are focused on the growth of the deposit:

  • To grow the existing resource model by increasing the length, depth and scale of the four currently modelled structures
  • To grow the existing resource model by increasing the number of formally modelled veins to at least ten
  • To demonstrate that the project has potential for significant new discoveries, particularly in the as yet undrilled Southern block.

With these objectives in mind we hope you will join us on this journey and follow along with our progress. We will have many developments to report on in the coming days and weeks. We are very grateful for your continued trust and support and we wish you good health and much personal success in 2022.

John Carlesso, CEO
FenixOro Gold Corp

About FenixOro Gold Corp.
FenixOro Gold Corp is a Canadian company focused on acquiring and exploring gold projects with world class exploration potential in the most prolific gold producing regions of Colombia. FenixOro’s flagship property, the Abriaqui project, is the closest project to Continental Gold’s Buritica project. It is located 15 km to the west in Antioquia State at the northern end of the Mid-Cauca gold belt, a geological trend which has seen multiple large gold discoveries in the past 10 years including Buritica and Anglo Gold’s Nuevo Chaquiro and La Colosa. As documented in “NI 43-101 Technical Report on the Abriaqui project Antioquia State, Colombia” (December 5, 2019), the geological characteristics of Abriaqui and Buritica are similar. Since the preparation of this report a Phase 1 drilling program has been completed at Abriaqui resulting in a significant discovery of a high grade, “Buritica style” gold deposit. A Phase 2 drilling program has recently commenced.

FenixOro’s VP of Exploration, Stuart Moller, led the discovery team at Buritica for Continental Gold in 2007-2011. At the time of its latest public report, the Buritica Mine contains measured plus indicated resources of 5.32 million ounces of gold (16.02 Mt grading 10.32 g/t) plus a 6.02 million ounce inferred resource (21.87 Mt grading 8.56 g/t) for a total of 11.34 million ounces of gold resources Buritica began formal production in November 2020 and has expected annual average production of 250,000 ounces at an all-in sustaining cost of approximately US$600 per ounce. Resources, cost and production data are taken from Continental Gold’s “NI 43-101 Buritica Mineral Resource 2019-01, Antioquia, Colombia, 18 March, 2019”). Continental Gold was recently the subject of a takeover by Zijin Mining in an all-cash transaction valued at C$1.4 billion.

Cautionary Statement on Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of FenixOro’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “will”, “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein include, but are not limited to information concerning the closing of the Private Placement, and Abriaqui. Although FenixOro believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that Abriaqui will produce viable quantities of minerals, that the Company will pursue Abriaqui or that any mineral deposits will be found, or that the Private Placement will close. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and FenixOro does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.

FenixOro Gold Corp
John Carlesso, CEO
Email: info@FenixOro.com
Website: www.FenixOro.com
Telephone: 1-833-ORO-GOLD

Capstone Green Energy (NASDAQ:CGRN) Signs with Global RAIS(R) as Its Solar PV Partner for the Growing Commercial & Industrial Microgrid Market

Posted on by Admin

 


Capstone Green Energy (NASDAQ:CGRN) Signs with Global RAIS(R) as Its Solar PV Partner for the Growing Commercial & Industrial Microgrid Market

Research, News, and Market Data on Capstone Green Energy

 

Global RAIS® Is a Provider of Modular, Low Voltage, Kit-Based Solar PV Solutions That Are Efficient, Reliable, Ultra-Safe, Resilient & Cost-Effective

VAN NUYS, CA / ACCESSWIRE / January 6, 2022 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) (“Capstone” or the “Company”), a global leader in carbon reduction and on-site resilient green energy solutions, announced today that it has entered into a supply agreement with Global RAIS® Energy & Storage Solutions (www.globalrais.com) (“Global RAIS”) for the supply of modular, low voltage, DC to DC solar photovoltaic (PV) kits for use in Capstone’s Commercial and Industrial-focused microgrid solutions.

Capstone Green Energy is partnering with Global RAIS® because their solar energy systems offer a robust suite of advantages over conventional solar at a competitive price. The key advantages leading to Capstone’s selection are as follows:

Energy Density:
The Global RAIS® APEX II DUO 450W and 515W modules offer very high power density per square foot of rooftop, which is critical for Capstone Green Energy’s commercial and industrial microgrid customers.

Grid Independence:
The Global RAIS® systems are compatible with point-of-use system without a grid connection and offer the command and control of array and inverters for microgrid and grid-connected systems, which are key for Capstone’s remote hospitality, telecom, and oil and gas customers.

Redundant Solar Solution:
Unlike conventional solar PV, every element of the Global RAIS® system has multiple connections so there are no single point failures; this makes the entire system highly robust and resilient. System reliability and resiliency are a cornerstone of Capstone’s value proposition with its commercial and industrial microgrid solutions.

Battery Storage-Ready Solution:
Global RAIS® intelligent modules can charge batteries directly from the modules for true DC to DC storage, which is beneficial to Capstone’s microgrid solutions. Additionally, the systems naturally fit with Capstone’s 48V battery storage solutions.

Reliable and Robust Product:
The Global RAIS® modules utilize a matrix topology and proprietary aluminum back sheet with integrated module-level controllers, offering a more robust real-world resiliency which is critical for some of Capstone’s end-use customers in remote and harsh environments.

Ease of Maintenance:
Global RAIS® has a smart low voltage design (< 60V DC) which makes maintaining a device safe and easy, eliminating the need for costly installation specialists. The systems are low weight and require no roof penetrations.

“We did a significant amount of research to find the right private label solar PV partner with the right technology to help Capstone Green Energy’s customers meet their carbon reduction goals at a realistic cost,” said Capstone Green Energy Chief Executive Officer, Darren Jamison. “After considering several photovoltaic products on the market, Capstone selected Global RAIS® because their product best meets the requirements of most of our commercial and industrial microgrid customers, at a competitive cost.”

“Global RAIS® is proud to partner with Capstone Green Energy as a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their carbon reduction, energy savings and resiliency goals,” stated Bob Vanderhoff, Chief Executive Officer of Global RAIS® Energy & Storage Solutions.

Global RAIS® Energy and Storage Solutions purchased the intellectual property (IP) and related assets of tenKsolar® in 2019. The Global RAIS® solar technology has been deployed at almost 3,000 installations worldwide since 2008.

About Capstone Green Energy
Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Generation Technologies (EGT) are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Solutions (ESS) business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen & Sustainable Products (H&S), Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three fiscal years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

About Global RAIS® Energy and Storage Solutions
Global RAIS® Energy and Storage Solutions (www.globalrais.com) provides modular, low voltage, kit-based solar PV solutions that are efficient, reliable, and cost-effective. Its lightweight, ballasted systems are easy and safe to install, requiring less man-hours and reducing the cost for installation. Global RAIS’s ultra-safe systems can be adapted for small to mid-size off-grid and grid-tied installations and feature a unique DC to DC storage capability. Our highly resilient systems are more reliable in harsh and extreme environments.

Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Posted on by Admin



Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Research, News, and Market Data on Cocrystal Pharma

 

Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022

BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery. The FDA’s guidance was received in a written response to Cocrystal’s pre-Investigational New Drug (IND) briefing package that was submitted in October 2021.

“The FDA’s response contained extensive and valuable responses to a list of questions we proposed in our pre-IND briefing package, providing key insights on advancing the non-clinical and clinical development of CDI-45205,” said Sam Lee, Ph.D., President and interim co-CEO of Cocrystal. “The FDA’s guidance marks an important milestone in our continued development of CDI-45205. We now have a clearer pathway for our planned Phase 1 single-ascending-dose and multiple-ascending-dose study that we expect to initiate in 2022, as well as directives for designing a subsequent Phase 2 study.”

The FDA’s response covered topics including preclinical studies, manufacturing, pharmacology and toxicology, and clinical development plans for CDI-45205 for Phase 1 and Phase 2 studies. In preparation for clinical development, Cocrystal intends to conduct CDI-45205 formulation development, IND-enabling studies and virology assessments, as well as API drug manufacturing for use in preclinical and clinical studies.

CDI-45205 is one of three COVID-19 programs underway at Cocrystal. In the second COVID-19 program, the Company plans to begin a Phase 1 study also in 2022 with an orally administered main protease inhibitor. In the third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover replication inhibitors for oral administration.

“Our COVID-19 programs feature novel inhibitors that are specifically designed to block viral replication of SARS-CoV-2,” said James Martin, Cocrystal’s CFO and interim co-CEO. “Our inhibitors have shown antiviral activity against various SARS-CoV-2 variants to date, including the Alpha, Beta, Gamma and Delta variants, and now even the Omicron variant. CDI-45205 is not a quick-to-market repurposed drug. Because of its design, we remain highly confident in the broad-spectrum antiviral ability of our compound CDI-45205 in addressing SARS-CoV-2 and variants.”

About CDI-45205
CDI-45205 is among a group of protease inhibitors obtained by Cocrystal under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020. CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2), Gamma (Brazil/P.1), Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the original Wuhan strain. CDI-45205 has also shown good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection, and no cytotoxicity against a variety of human cell lines. Preclinical research demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir. Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in mice infected with MERS-CoV-2.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans to initiate two Phase 1 studies in 2022, our further development of CDI-45205 and using its platform to discover replication inhibitors, and the potential efficacy of antiviral inhibitors against existing and new variants of COVID-19. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from supply chain disruptions on our ability to obtain products including raw materials and test animals as well as similar problems with our vendors and our current CRO and future CROs and CMOs, the impact of the COVID-19 pandemic including new variants on the national and global economy, the cooperation of the FDA in accelerating development in our COVID-19 program, our collaboration partners’ technology and software performing as expected, the results of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Source: Cocrystal Pharma, Inc.

BioSig to Present at the 24th Annual Virtual Needham Growth Conference

Posted on by Admin



BioSig to Present at the 24th Annual Virtual Needham Growth Conference

News and Market Data on BioSig Technologies

 

BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System.

Westport, CT, Jan. 06, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it it will present at the 24th Annual Virtual Needham Growth Conference on Friday, January 14th , 2022 at 4:15 PM ET.

To register for the live webcast of the event, please click here.

A replay of the presentation will also be available on the BioSig Website.

For parties interested in scheduling a one-on-one meeting with BioSig management, please contact your Needham representative.

The PURE EP™ is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. Clinical data acquired by the PURE EP™ System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™  signals over conventional sources.

One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. (www.biosig.com).

The Company’s first product, PURE EP ™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. To date, 73 physicians have completed over 1,800 patient cases with the PURE EP™ System. The Company is in a focused commercial launch of the PURE EP™ System in the Northeast, Texas, and Florida. The technology is regularly used in some of the country’s highest-ranked hospitals, including St. David’s Medical Center in Austin, TX, Mayo Clinic campuses in Florida, Minnesota, and Arizona, and University of Pennsylvania in Philadelphia, PA.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

1 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

Source: BioSig Technologies, Inc.

Will the Jump in Uranium Prices Impact Mining Stocks?

Posted on by Admin 


	Image Credit: IAEA Imagebank (Flickr)

Natural Gas Protests in Kazakhstan May Impact Global Fuel Costs Across the Board

 

Uranium futures are having their best week since early October. This is the result of protests in Kazakhstan that began Monday over an increase in natural gas costs. Natural gas powers most cars in the country of 19 million.  The protests are important to investors globally as Kazakhstan is a large energy producer, including 40% of the world’s uranium production. The country also has an abundance of other natural resources, including oil, gas, copper, and coal. Additionally, Kazakhstan has recently become a popular center for Bitcoin mining.

Crackdowns on protesters have impacted business. The government has suspended all operations of financial institutions including banks and the stock exchange, it has also disrupted communications. The situation continues to escalate despite Russia sending in “peacekeeping forces” to the former Soviet nation. There are reports of injuries and deaths of both protesters and police.


Impact on Uranium

As the world’s largest producer of uranium, any long-term disruption could impact prices and future supply. The price of uranium which is up 48.12% YOY, has traded higher on news this week of the protests and crackdown. Mining companies that operate outside of Kazakhstan have experienced upward pressure on their shares since the start of the year/week.

 

Data Source: Koyfin

 

Uranium Explorers/Producers With Operations in the Americas

While uranium stocks rose with uranium futures earlier this week, many have dipped as investors have now taken a wait-and-see stance. Listed below are a few small and microcap companies involved in uranium production that may be worth keeping on your radar as new developments play out.

Uranium Energy Corp (NYSE/AM: UEC)  is an independent U.S. uranium mining company. The company controls 104M lbs. of qualified resources and a fully permitted uranium processing plant in South Texas. The company has a potential production profile of around 4 million pounds of U.S.-origin U3O8 per year with room to expand. UEC has a 52-week trading range of $1.51-$5.79 and is currently trading at $3.67.

Energy Fuels, Inc. (NYSE/AM:UUUU) is engaged in conventional and in-situ recovery (ISR) uranium extraction and recovery, along with exploration, permitting, and evaluation of properties in the United States. The Company conducts its ISR activities through its Nichols Ranch Project in northeast Wyoming and its Alta Mesa Project in south Texas. Detailed research including the Noble analyst 12-month
price target are available on Channelchek. UUUU has a 52-week trading range of $2.53-$11.39 and is currently trading at $7.90.

encore Energy Corp. (OTC/QB: ENCUF) is a diversified U.S. domestic uranium developer focused on becoming a leading ISR uranium producer. enCore’s initial opportunities are created from enCore’s licensed and past-producing South Texas-located Rosita and Kingsville Dome ISR production facilities, and multiple satellite projects in South Texas. ENCUF has a 52-week trading range of $0.64-$1.80 and is currently trading at $1.38.

Blue Sky Uranium (OTC/QB: BKUCF)     is a Canada-based junior mineral exploration company engaged in uranium and vanadium exploration in Argentina. It has approximately 4,000 square kilometers of prospective tenements. The Company’s projects include Amarillo Grande, Sierra Colonia, Tierras Coloradas, and Cerro Parva. The Amarillo Grande Project is located in central Rio Negro province, in the Patagonia region of southern Argentina. A video presentation by the company management is available on Channelchek’s YouTube Channel.

 

Take-Away

Natural resource prices have a long history of increased volatility as turmoil hits regions where there are major suppliers. Mineral-rich Kazakhstan is currently going through a period of public uprising with uncertain consequences. Investors in this sector should further refine their watch-list.

Uranium and uranium producers have over the past year been benefitting from the move to low or no carbon-emitting fuels. The sector gained a lot of attention last year as announcements for new nuclear plants and physical uranium ETFs were created. Channelchek has been reporting on these developments including a series of videos of management presentations we call Power Players. We invite you to uncover more insights into the uranium mining industry through these Power Player videos.

 

Suggested Reading:



Can You Invest in Uranium Directly?

The Increasing Popularity of Uranium Investments





How does the Gates Buffett Natrium Reactor Work?

Is Thorium, Not Uranium the Future of Power Generation?

 

Sources:

https://www.bloombergquint.com/markets/turmoil-in-uranium-rich-kazakhstan-threatens-to-elevate-prices

https://www.aljazeera.com/news/2022/1/5/explainer-what-is-behind-the-protests-rocking-kazakhstan

https://online.flipbuilder.com/noblecon/roqa/

https://www.barrons.com/articles/russian-intervention-in-kazakhstan-fuels-markets-concerns-51641467131

 

Stay up to date. Follow us:

 

Robinhood’s Move to Become More Traditional

Posted on by Admin 


	Image Credit: PiggyBank Canada (Flickr)

Robinhood Will Be Adopting More Traditional Investment Programs

 

Some of the trading patterns and techniques that once allowed brokerage app Robinhood (HOOD) to flourish have largely faded from popularity. This may be pushing the once disruptive newcomer to adopt more traditional investment tools and services.

 

News Out of
Robinhood

Robinhood Markets is adding a top executive with a traditional brokerage pedigree. They are adding him while they also plan to introduce new investment tools to guide investors into more accepted investing techniques. As the momentum that helped the company during the era when investors were locked down with their smartphone and their stimulus checks slowed, the company that went public in July 2021 at $38 has found its stock is now trading below $16. While some of the company’s more traditional peers have learned a few new business practices from Robinhood, in order to regain its footing, Robinhood is now adopting some more tried and true online brokerage practices.

The announcement on Wednesday (January 5) that it would appoint Steve Quirk, the former executive vice president of trading and education at TD Ameritrade, in a new position as chief brokerage officer may be welcome news for some stockholders. Mr. Quirk will be responsible for overseeing Robinhood Financial and Robinhood Securities which are the company’s broker-dealers. In its announcement, Robinhood highlighted the depth of Quirk’s 35 years of experience within the securities brokerage community.

 

Background

After Charles Schwab (SCHW) acquired TD Ameritrade, it was known that top executives from TD Ameritrade would be leaving after the transition. Robinhood has been viewed as a tech and data company that is in the securities business. Several of its top executives have been previously employed by Amazon (AMZN) and Alphabet (GOOGL), their focus is now broadening.

While the app’s technology may be easy to use, other brokerages are catching up. And relying heavily on meme stock fads and cryptocurrency trading may not be diversified enough for the company to withstand the test of time. The newer additions to its program will help users accumulate assets and follow a wealth accumulation strategy with less risk. This may be a safer road for both the company and the clients when compared to its history of free stock give-away for opening an account, and other game-like features to encourage usage.

While this is a significant step toward remaking Robinhood’s business model, the new direction could come at the expense of repetitive trades. More than three-quarters of Robinhood’s revenue comes from transactions. However, becoming less dependent on high-frequency traders and more on assets on the platform could level Robinhood’s earnings and lower the volatility in its own share price.

 

Suggested Reading:



From Robinhood to Rocket $HOOD

Robinhood’s IPO and its Place in Stock Market History





Can Small Investors Compete with Wall Street?

Cannabis Fundamentals Not Hype Important to Investors

 

Sources:

https://blog.robinhood.com/

https://www.thinkadvisor.com/2022/01/06/ex-td-ameritrade-exec-joins-robinhood-tech-roundup/?slreturn=20220006150524

https://www.barrons.com/articles/new-executive-hiring-highlights-a-shift-at-robinhood-51641433636

 

Stay up to date. Follow us:

 

Robinhoods Move to Become More Traditional

Posted on by Admin 


	Image Credit: PiggyBank Canada (Flickr)

Robinhood Will Be Adopting More Traditional Investment Programs

 

Some of the trading patterns and techniques that once allowed brokerage app Robinhood (HOOD) to flourish have largely faded from popularity. This may be pushing the once disruptive newcomer to adopt more traditional investment tools and services.

 

News Out of
Robinhood

Robinhood Markets is adding a top executive with a traditional brokerage pedigree. They are adding him while they also plan to introduce new investment tools to guide investors into more accepted investing techniques. As the momentum that helped the company during the era when investors were locked down with their smartphone and their stimulus checks slowed, the company that went public in July 2021 at $38 has found its stock is now trading below $16. While some of the company’s more traditional peers have learned a few new business practices from Robinhood, in order to regain its footing, Robinhood is now adopting some more tried and true online brokerage practices.

The announcement on Wednesday (January 5) that it would appoint Steve Quirk, the former executive vice president of trading and education at TD Ameritrade, in a new position as chief brokerage officer may be welcome news for some stockholders. Mr. Quirk will be responsible for overseeing Robinhood Financial and Robinhood Securities which are the company’s broker-dealers. In its announcement, Robinhood highlighted the depth of Quirk’s 35 years of experience within the securities brokerage community.

 

Background

After Charles Schwab (SCHW) acquired TD Ameritrade, it was known that top executives from TD Ameritrade would be leaving after the transition. Robinhood has been viewed as a tech and data company that is in the securities business. Several of its top executives have been previously employed by Amazon (AMZN) and Alphabet (GOOGL), their focus is now broadening.

While the app’s technology may be easy to use, other brokerages are catching up. And relying heavily on meme stock fads and cryptocurrency trading may not be diversified enough for the company to withstand the test of time. The newer additions to its program will help users accumulate assets and follow a wealth accumulation strategy with less risk. This may be a safer road for both the company and the clients when compared to its history of free stock give-away for opening an account, and other game-like features to encourage usage.

While this is a significant step toward remaking Robinhood’s business model, the new direction could come at the expense of repetitive trades. More than three-quarters of Robinhood’s revenue comes from transactions. However, becoming less dependent on high-frequency traders and more on assets on the platform could level Robinhood’s earnings and lower the volatility in its own share price.

 

Suggested Reading:



From Robinhood to Rocket $HOOD

Robinhood’s IPO and its Place in Stock Market History





Can Small Investors Compete with Wall Street?

Cannabis Fundamentals Not Hype Important to Investors

 

Sources:

https://blog.robinhood.com/

https://www.thinkadvisor.com/2022/01/06/ex-td-ameritrade-exec-joins-robinhood-tech-roundup/?slreturn=20220006150524

https://www.barrons.com/articles/new-executive-hiring-highlights-a-shift-at-robinhood-51641433636

 

Stay up to date. Follow us:

 

Will the Jump in Uranium Prices Impacting Mining Stocks

Posted on by Admin 


	Image Credit: IAEA Imagebank (Flickr)

Natural Gas Protests in Kazakhstan May Impact Global Fuel Costs Across the Board

 

Uranium futures are having their best week since early October. This is the result of protests in Kazakhstan that began Monday over an increase in natural gas costs. Natural gas powers most cars in the country of 19 million.  The protests are important to investors globally as Kazakhstan is a large energy producer, including 40% of the world’s uranium production. The country also has an abundance of other natural resources, including oil, gas, copper, and coal. Additionally, Kazakhstan has recently become a popular center for Bitcoin mining.

Crackdowns on protesters have impacted business. The government has suspended all operations of financial institutions including banks and the stock exchange, it has also disrupted communications. The situation continues to escalate despite Russia sending in “peacekeeping forces” to the former Soviet nation. There are reports of injuries and deaths of both protesters and police.


Impact on Uranium

As the world’s largest producer of uranium, any long-term disruption could impact prices and future supply. The price of uranium which is up 48.12% YOY, has traded higher on news this week of the protests and crackdown. Mining companies that operate outside of Kazakhstan have experienced upward pressure on their shares since the start of the year/week.

 

Data Source: Koyfin

 

Uranium Explorers/Producers With Operations in the Americas

While uranium stocks rose with uranium futures earlier this week, many have dipped as investors have now taken a wait-and-see stance. Listed below are a few small and microcap companies involved in uranium production that may be worth keeping on your radar as new developments play out.

Uranium Energy Corp (NYSE/AM: UEC)  is an independent U.S. uranium mining company. The company controls 104M lbs. of qualified resources and a fully permitted uranium processing plant in South Texas. The company has a potential production profile of around 4 million pounds of U.S.-origin U3O8 per year with room to expand. UEC has a 52-week trading range of $1.51-$5.79 and is currently trading at $3.67.

Energy Fuels, Inc. (NYSE/AM:UUUU) is engaged in conventional and in-situ recovery (ISR) uranium extraction and recovery, along with exploration, permitting, and evaluation of properties in the United States. The Company conducts its ISR activities through its Nichols Ranch Project in northeast Wyoming and its Alta Mesa Project in south Texas. Detailed research including the Noble analyst 12-month
price target are available on Channelchek. UUUU has a 52-week trading range of $2.53-$11.39 and is currently trading at $7.90.

encore Energy Corp. (OTC/QB: ENCUF) is a diversified U.S. domestic uranium developer focused on becoming a leading ISR uranium producer. enCore’s initial opportunities are created from enCore’s licensed and past-producing South Texas-located Rosita and Kingsville Dome ISR production facilities, and multiple satellite projects in South Texas. ENCUF has a 52-week trading range of $0.64-$1.80 and is currently trading at $1.38.

Blue Sky Uranium (OTC/QB: BKUCF)     is a Canada-based junior mineral exploration company engaged in uranium and vanadium exploration in Argentina. It has approximately 4,000 square kilometers of prospective tenements. The Company’s projects include Amarillo Grande, Sierra Colonia, Tierras Coloradas, and Cerro Parva. The Amarillo Grande Project is located in central Rio Negro province, in the Patagonia region of southern Argentina. A video presentation by the company management is available on Channelchek’s YouTube Channel.

 

Take-Away

Natural resource prices have a long history of increased volatility as turmoil hits regions where there are major suppliers. Mineral-rich Kazakhstan is currently going through a period of public uprising with uncertain consequences. Investors in this sector should further refine their watch-list.

Uranium and uranium producers have over the past year been benefitting from the move to low or no carbon-emitting fuels. The sector gained a lot of attention last year as announcements for new nuclear plants and physical uranium ETFs were created. Channelchek has been reporting on these developments including a series of videos of management presentations we call Power Players. We invite you to uncover more insights into the uranium mining industry through these Power Player videos.

 

Suggested Reading:



Can You Invest in Uranium Directly?

The Increasing Popularity of Uranium Investments





How does the Gates Buffett Natrium Reactor Work?

Is Thorium, Not Uranium the Future of Power Generation?

 

Sources:

https://www.bloombergquint.com/markets/turmoil-in-uranium-rich-kazakhstan-threatens-to-elevate-prices

https://www.aljazeera.com/news/2022/1/5/explainer-what-is-behind-the-protests-rocking-kazakhstan

https://online.flipbuilder.com/noblecon/roqa/

https://www.barrons.com/articles/russian-intervention-in-kazakhstan-fuels-markets-concerns-51641467131

 

Stay up to date. Follow us:

 

Release – Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Posted on by Admin



Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Research, News, and Market Data on Cocrystal Pharma

 

Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022

BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery. The FDA’s guidance was received in a written response to Cocrystal’s pre-Investigational New Drug (IND) briefing package that was submitted in October 2021.

“The FDA’s response contained extensive and valuable responses to a list of questions we proposed in our pre-IND briefing package, providing key insights on advancing the non-clinical and clinical development of CDI-45205,” said Sam Lee, Ph.D., President and interim co-CEO of Cocrystal. “The FDA’s guidance marks an important milestone in our continued development of CDI-45205. We now have a clearer pathway for our planned Phase 1 single-ascending-dose and multiple-ascending-dose study that we expect to initiate in 2022, as well as directives for designing a subsequent Phase 2 study.”

The FDA’s response covered topics including preclinical studies, manufacturing, pharmacology and toxicology, and clinical development plans for CDI-45205 for Phase 1 and Phase 2 studies. In preparation for clinical development, Cocrystal intends to conduct CDI-45205 formulation development, IND-enabling studies and virology assessments, as well as API drug manufacturing for use in preclinical and clinical studies.

CDI-45205 is one of three COVID-19 programs underway at Cocrystal. In the second COVID-19 program, the Company plans to begin a Phase 1 study also in 2022 with an orally administered main protease inhibitor. In the third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover replication inhibitors for oral administration.

“Our COVID-19 programs feature novel inhibitors that are specifically designed to block viral replication of SARS-CoV-2,” said James Martin, Cocrystal’s CFO and interim co-CEO. “Our inhibitors have shown antiviral activity against various SARS-CoV-2 variants to date, including the Alpha, Beta, Gamma and Delta variants, and now even the Omicron variant. CDI-45205 is not a quick-to-market repurposed drug. Because of its design, we remain highly confident in the broad-spectrum antiviral ability of our compound CDI-45205 in addressing SARS-CoV-2 and variants.”

About CDI-45205
CDI-45205 is among a group of protease inhibitors obtained by Cocrystal under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020. CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2), Gamma (Brazil/P.1), Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the original Wuhan strain. CDI-45205 has also shown good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection, and no cytotoxicity against a variety of human cell lines. Preclinical research demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir. Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in mice infected with MERS-CoV-2.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans to initiate two Phase 1 studies in 2022, our further development of CDI-45205 and using its platform to discover replication inhibitors, and the potential efficacy of antiviral inhibitors against existing and new variants of COVID-19. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from supply chain disruptions on our ability to obtain products including raw materials and test animals as well as similar problems with our vendors and our current CRO and future CROs and CMOs, the impact of the COVID-19 pandemic including new variants on the national and global economy, the cooperation of the FDA in accelerating development in our COVID-19 program, our collaboration partners’ technology and software performing as expected, the results of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Source: Cocrystal Pharma, Inc.

Release – Capstone Green Energy Signs with Global RAIS as Its Solar PV Partner

Posted on by Admin

 


Capstone Green Energy (NASDAQ:CGRN) Signs with Global RAIS(R) as Its Solar PV Partner for the Growing Commercial & Industrial Microgrid Market

Research, News, and Market Data on Capstone Green Energy

 

Global RAIS® Is a Provider of Modular, Low Voltage, Kit-Based Solar PV Solutions That Are Efficient, Reliable, Ultra-Safe, Resilient & Cost-Effective

VAN NUYS, CA / ACCESSWIRE / January 6, 2022 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) (“Capstone” or the “Company”), a global leader in carbon reduction and on-site resilient green energy solutions, announced today that it has entered into a supply agreement with Global RAIS® Energy & Storage Solutions (www.globalrais.com) (“Global RAIS”) for the supply of modular, low voltage, DC to DC solar photovoltaic (PV) kits for use in Capstone’s Commercial and Industrial-focused microgrid solutions.

Capstone Green Energy is partnering with Global RAIS® because their solar energy systems offer a robust suite of advantages over conventional solar at a competitive price. The key advantages leading to Capstone’s selection are as follows:

Energy Density:
The Global RAIS® APEX II DUO 450W and 515W modules offer very high power density per square foot of rooftop, which is critical for Capstone Green Energy’s commercial and industrial microgrid customers.

Grid Independence:
The Global RAIS® systems are compatible with point-of-use system without a grid connection and offer the command and control of array and inverters for microgrid and grid-connected systems, which are key for Capstone’s remote hospitality, telecom, and oil and gas customers.

Redundant Solar Solution:
Unlike conventional solar PV, every element of the Global RAIS® system has multiple connections so there are no single point failures; this makes the entire system highly robust and resilient. System reliability and resiliency are a cornerstone of Capstone’s value proposition with its commercial and industrial microgrid solutions.

Battery Storage-Ready Solution:
Global RAIS® intelligent modules can charge batteries directly from the modules for true DC to DC storage, which is beneficial to Capstone’s microgrid solutions. Additionally, the systems naturally fit with Capstone’s 48V battery storage solutions.

Reliable and Robust Product:
The Global RAIS® modules utilize a matrix topology and proprietary aluminum back sheet with integrated module-level controllers, offering a more robust real-world resiliency which is critical for some of Capstone’s end-use customers in remote and harsh environments.

Ease of Maintenance:
Global RAIS® has a smart low voltage design (< 60V DC) which makes maintaining a device safe and easy, eliminating the need for costly installation specialists. The systems are low weight and require no roof penetrations.

“We did a significant amount of research to find the right private label solar PV partner with the right technology to help Capstone Green Energy’s customers meet their carbon reduction goals at a realistic cost,” said Capstone Green Energy Chief Executive Officer, Darren Jamison. “After considering several photovoltaic products on the market, Capstone selected Global RAIS® because their product best meets the requirements of most of our commercial and industrial microgrid customers, at a competitive cost.”

“Global RAIS® is proud to partner with Capstone Green Energy as a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their carbon reduction, energy savings and resiliency goals,” stated Bob Vanderhoff, Chief Executive Officer of Global RAIS® Energy & Storage Solutions.

Global RAIS® Energy and Storage Solutions purchased the intellectual property (IP) and related assets of tenKsolar® in 2019. The Global RAIS® solar technology has been deployed at almost 3,000 installations worldwide since 2008.

About Capstone Green Energy
Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Generation Technologies (EGT) are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Solutions (ESS) business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen & Sustainable Products (H&S), Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three fiscal years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

About Global RAIS® Energy and Storage Solutions
Global RAIS® Energy and Storage Solutions (www.globalrais.com) provides modular, low voltage, kit-based solar PV solutions that are efficient, reliable, and cost-effective. Its lightweight, ballasted systems are easy and safe to install, requiring less man-hours and reducing the cost for installation. Global RAIS’s ultra-safe systems can be adapted for small to mid-size off-grid and grid-tied installations and feature a unique DC to DC storage capability. Our highly resilient systems are more reliable in harsh and extreme environments.

Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

Release – FenixOro Provides Letter to Investors Outlining Plans for 2022

Posted on by Admin



FenixOro Provides Letter to Investors Outlining Plans for 2022

Research, News, and Market Data on FenixOro Gold

 

TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) — FenixOro Gold Corp. (CSE: FENX; OTCQB: FDVXF; Frankfurt: 8FD) is pleased to provide an update to shareholders and investors as the Company kicks off its plans for 2022.

As we set out on a new year we wanted to share with you our objectives for what we believe will be an exciting time as we accelerate the exploration program at the Abriaqui gold project.

Our plans for 2022 are being driven by the tremendous success we had last year. The achievements were many. To provide some context for the upcoming program, here are some of the key developments we announced last year (www.fenixoro.com/news-events/press-releases/)

2021 Highlights

  • The significant discovery of a new zone with multiple high grade intercepts including 124 g/t gold (February 24/21)
  • Extending strike length of 1400m on the main Santa Teresa vein (March 15/21)
  • Completion of Phase 1 drilling and the establishment of a preliminary minimum target resource model of 1.6 – 2.4 million oz (March 19/21)
  • Demonstrating the significant vertical continuity of high grade mineralization, a minimum of 1200 meters (March 19/21)
  • The commencement of Phase 2 drilling (April 26/21)
  • Significant soil anomalies generated large target areas in the undrilled Southern block (May 10/21)
  • True-width channel sample intercept of 11.4m of 6.08 g/t gold on the main Santa Teresa vein system (August 5/21)
  • Noble Capital Markets initiated research coverage (September 13/21)
  • Intercepted 23.2 g/t gold in the newly discovered Cascada vein (September 28/21)
  • Closing on a first tranche private placement financing of $2.4 million (December 8/21)
  • Cormark Securities issued a report following a site visit by Mining Analyst Brock Colterjohn (December 9/21)

One of the main challenges we faced in 2021 was the turnaround time it took to receive assay results from the lab – at times this ran ten to twelve weeks due to global supply issues. We have addressed this and are now using a new lab that is providing results on a fourteen day turnaround. This should provide us with a much more consistent data and news flow. We are currently in the midst of a major data compilation exercise that we expect will generate new interpretations as well as high-interest target areas.

Looking Forward
With the foundation of the success we experienced in 2021 we are extremely optimistic on the outlook for 2022. It is still very early in the exploration cycle of the project and yet we are already demonstrating that Abriaqui has the potential to be a significant and very special asset.

The three key objectives of this year’s program are focused on the growth of the deposit:

  • To grow the existing resource model by increasing the length, depth and scale of the four currently modelled structures
  • To grow the existing resource model by increasing the number of formally modelled veins to at least ten
  • To demonstrate that the project has potential for significant new discoveries, particularly in the as yet undrilled Southern block.

With these objectives in mind we hope you will join us on this journey and follow along with our progress. We will have many developments to report on in the coming days and weeks. We are very grateful for your continued trust and support and we wish you good health and much personal success in 2022.

John Carlesso, CEO
FenixOro Gold Corp

About FenixOro Gold Corp.
FenixOro Gold Corp is a Canadian company focused on acquiring and exploring gold projects with world class exploration potential in the most prolific gold producing regions of Colombia. FenixOro’s flagship property, the Abriaqui project, is the closest project to Continental Gold’s Buritica project. It is located 15 km to the west in Antioquia State at the northern end of the Mid-Cauca gold belt, a geological trend which has seen multiple large gold discoveries in the past 10 years including Buritica and Anglo Gold’s Nuevo Chaquiro and La Colosa. As documented in “NI 43-101 Technical Report on the Abriaqui project Antioquia State, Colombia” (December 5, 2019), the geological characteristics of Abriaqui and Buritica are similar. Since the preparation of this report a Phase 1 drilling program has been completed at Abriaqui resulting in a significant discovery of a high grade, “Buritica style” gold deposit. A Phase 2 drilling program has recently commenced.

FenixOro’s VP of Exploration, Stuart Moller, led the discovery team at Buritica for Continental Gold in 2007-2011. At the time of its latest public report, the Buritica Mine contains measured plus indicated resources of 5.32 million ounces of gold (16.02 Mt grading 10.32 g/t) plus a 6.02 million ounce inferred resource (21.87 Mt grading 8.56 g/t) for a total of 11.34 million ounces of gold resources Buritica began formal production in November 2020 and has expected annual average production of 250,000 ounces at an all-in sustaining cost of approximately US$600 per ounce. Resources, cost and production data are taken from Continental Gold’s “NI 43-101 Buritica Mineral Resource 2019-01, Antioquia, Colombia, 18 March, 2019”). Continental Gold was recently the subject of a takeover by Zijin Mining in an all-cash transaction valued at C$1.4 billion.

Cautionary Statement on Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of FenixOro’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “will”, “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein include, but are not limited to information concerning the closing of the Private Placement, and Abriaqui. Although FenixOro believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that Abriaqui will produce viable quantities of minerals, that the Company will pursue Abriaqui or that any mineral deposits will be found, or that the Private Placement will close. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and FenixOro does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.

FenixOro Gold Corp
John Carlesso, CEO
Email: info@FenixOro.com
Website: www.FenixOro.com
Telephone: 1-833-ORO-GOLD